Health CanadaGeneral Alert
MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke (...
Published: June 22, 2020Recall ID: 61388Category: generalCountry: Canada
Reason for Recall / Hazard
Product safety
Product Description & Identification
MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis
Additional Source Details
| Field | Value |
|---|---|
| N I D | 61388 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/mabcampath-alemtuzumab-risk-haemophagocytic-lymphohistiocytosis-stroke-including |
| Issue | Product safety |
| Title | MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2020-06-22 |
| Organization | Marketed health products |